即将报上市！新一代口服 SERD 药物联用 CDK4/6 抑制剂 III 期成功
2 月 26日，阿斯利康宣布SERENA-6 III 期临床试验中， Camizestrant 在一线晚期 HR 阳性乳腺癌（伴 ESR1 肿瘤突变）患者中表现出高度统计学显著和临床意义的 ...
阿思達克財經網2 小时
阿斯利康(AZN.US)口服小分子疗法3期临床试验结果积极
智通财经APP获悉，2月27日，阿斯利康 (AZN.US) 宣布，3期临床试验SERENA-6的中期分析显示，其在研口服选择性雌激素受体降解剂 (SERD)camizestrant与CDK4/6抑制剂联用，在主要终点无进展生存期 ...
阿斯利康乳腺癌治疗取得重大突破
SERENA-6试验是首个采用ctDNA指导方法的全球双盲III期研究，结果显示，与继续接受芳香化酶抑制剂标准治疗的患者相比，转换为camizestrant联合CDK4/6抑制剂治疗的患者疾病进展时间明显延长。虽然总生存期和第二次疾病进展时间等次要终点仍在评估中，但已观察到改善趋势。
AstraZeneca therapy improves breast cancer survival in key trial
Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...
PMLiVE20 小时
AstraZeneca’s camizestrant shows promise in phase 3 breast cancer study
The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...
AstraZeneca's camizestrant shows promise in breast cancer trial
AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and ...
AstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage Trial
The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...
AstraZeneca's Investigational Cancer Drug Shows First-Line Benefit In Combination With ...
AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.
AstraZeneca reports SERENA-6 trial shows improvement in the primary endpoint
Results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in combination with a ...
AstraZeneca therapy improves survival in late-stage breast cancer trial
Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in ...
AstraZeneca: Camizestrant Improved PFS in 1L HR+ Breast Cancer
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...